Overview

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if paroxetine and fluconazole are safe and effective as a treatment for problems with memory, concentration, thinking, and judgment in people who are infected with HIV. Paroxetine is an antidepressant approved by the FDA to treat major depression. Fluconazole is an antifungal medication approved by the FDA to treat fungal infections.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

National Institute of Mental Health (NIMH)

Treatments:

Fluconazole
Paroxetine